BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2002

View Archived Issues

LG Chem regains worldwide rights to late-stage quinolone antibiotic

Read More

Novel antibacterial agents effective against resistant microorganisms discovered at eXegenics

Read More

Antiangiogenic DAC-based peptides presented by ConjuChem

Read More

Antimetastatic and antitumor agents targeting uPA system discussed by Wilex at AACR meeting

Read More

Maxia research on inhibitors of MKP-1 as potential anticancer agents presented to AACR

Read More

Antisense Rad51 inhibitors designed at Pangene for sensitizing tumor cells to DNA damage

Read More

Novel class of potent cytotoxic tubulin-interacting agents identified by Zentaris

Read More

TNP-470 and docetaxel as combination therapy for transitional cell carcinoma of the bladder

Read More

Palonosetron effective for the treatment of chemotherapy-induced nausea and vomiting

Read More

Japanese researchers report new preclinical data on the 5alpha-reductase inhibitor TF-505

Read More

Isoliquiritigenin shows potential as a prostate cancer preventive

Read More

Snapshots of new roles for testosterone in neurological and cardiac disorders

Read More

Positive 24-week results from first phase III trial of T-20

Read More

Irofulven trial in refractory pancreatic cancer discontinued

Read More

Novogen's phenoxodiol stabilizes tumor growth with minimal toxicity

Read More

Spiriva approved in E.U. under mutual recognition procedure

Read More

NT-13 enhances memory and learning, protects neural tissue and alleviates neuropathic pain

Read More

FDA approves Botox Cosmetic for treatment of glabellar lines

Read More

Phytopharm completes installation of P-57 manufacturing plant

Read More

Novo Nordisk plans to outlicense NN-622

Read More

Phase I/II trial of Civacir to prevent HCV reinfection following liver transplant

Read More

Endothelin receptor antagonists with utility in hypertension, etc.

Read More

Antifungal agents described in patent by Oxford GlycoSciences

Read More

Nonabsorbable antibiotics for treatment of gastrointestinal disorders

Read More

FT-0554A prepared by Kitasato Institute

Read More

Lilly claims agonists of PPARalpha and PPARgamma in recent patent

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing